- ►annals.org [PDF] R Loomba, A Rowley, R Wesley, TJ Liang, JH … - Annals of internal medicine, 2008 - Am Coll Physicians Background: Lamivudine is increasingly being used to prevent hepatitis B
reactivation in patients with cancer who test positive for hepatitis B surface
antigen (HBsAg) and are undergoing chemo- therapy. Cited by 37 - Related articles - BL Direct - All 6 versions
C Hsu, CA Hsiung, IJ Su, WS Hwang, MC Wang … - Hepatology, 2008 - nhri.org.tw Lamivudine is effective to control hepatitis B virus (HBV) reactivation in
HBV-carrying cancer patients who undergo chemotherapy, but the optimal treatment
protocol remains undetermined. In this study, HBV carriers with newly ... Cited by 32 - Related articles - View as HTML - BL Direct - All 9 versions
LH Katz, A Fraser, A Gafter-Gvili, L Leibovici, … - Journal of Viral Hepatitis, 2008 - medscape.com To assess the effects of prophylactic lamivudine on reactivation and mortality
following immunosuppressive therapy in hepatitis B surface antigen
(HBsAg)-positive patients, we performed a meta-analysis. Systematic review ... Cited by 15 - Related articles - BL Direct - All 7 versions
R Dillon, GM Hirschfield, MED Allison, KP … - British Medical Journal, 2008 - bmj.com You are seeing this message because your web browser does not support basic web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... The first 150 words of ... Cited by 7 - Related articles - All 3 versions
S Saab, MH Dong, TA Joseph, MJ Tong - Hepatology, 2007 - interscience.wiley.com Hepatitis B reactivation is a major cause of morbidity and mortality in patients
undergoing chemotherapy for lymphomas. These patients may experience direct
liver-related complications or reduced cancer survival because of ... Cited by 13 - Related articles - BL Direct - All 2 versions
- ►bmj.com CK Hui, WWW Cheung, WY Au, AKW Lie, HY … - British Medical Journal, 2005 - gut.bmj.com Results: Median time of follow up after withdrawal of lamivudine was 25.7 (range
5.7–75.7) months. Eleven of the 46 patients (23.9%) developed HBV reactivation
after withdrawal of pre-emptive lamivudine. Eight of the 16 patients with ... Cited by 66 - Related articles - All 12 versions
CM Weinbaum, I Williams, EE Mast, SA Wang, L … - MMWR Recomm Rep, 2008 - cdc.gov Serologic testing for hepatitis B surface antigen (HBsAg) is the primary way to
identify persons with chronic hepatitis B virus (HBV) infection. Testing has
been recommended previously for pregnant women, infants born to ... Cited by 22 - Related articles - Cached - All 6 versions
HE Kohrt, DL Ouyang, EB Keeffe… - Aliment Pharmacol Ther, 2006 - medscape.com In 1995, early reports of lamivudine, a reverse-transcriptase inhibitor
(3'-thiacytidine), which results in suppression of HBV replication by causing
early chain termination, appeared promising for the treatment of chronic ... Cited by 41 - Related articles - BL Direct - All 9 versions
JK Law, JK Ho, PJ Hoskins, SR Erb, UP … - Leukemia & lymphoma, 2005 - informahealthcare.com Abstract In the absence of prophylaxis, the reactivation of hepatitis B in
oncology patients who are hepatitis B carriers is a well-known and often fatal
complication of chemotherapy. The current recommendations in Canada and the ... Cited by 53 - Related articles - All 6 versions
GKK Lau, HHY Yiu, DYT Fong, HC Cheng, WY … - Gastroenterology, 2003 - Elsevier Hepatitis B virus reactivation is a serious cause of morbidity and mortality in
hepatitis B surface antigen-positive patients treated with chemotherapy. We
compared the efficacy of early and deferred preemptive lamivudine therapy ... Cited by 130 - Related articles - BL Direct - All 10 versions
